Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 372 • 2012 ACR/ARHP Annual Meeting
TRAF1/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis
Helena Canhao¹, Ana M. Rodrigues², Maria José Santos³, Diana Carmona-Fernandes⁴, Bruno Bettencourt⁵, Jing Cui⁶, Fabiana Rocha⁵, Jose canas Silva³, Joaquim Polido Pereira⁷, Jose Alberto Pereira Silva⁸, José Antonio Costa⁹, Domingos Araujo¹⁰, Candida Silva¹¹, Helena Santos¹², Catia Duarte¹³, Fernando Pimentel-Santos¹⁴, Jaime C. Branco¹⁴, Robert M. Plenge¹⁵, Daniel H. Solomon¹⁶, Jacome Bruges Armas⁵, José A. P. Da Silva¹⁷, João E. Fonseca¹⁸ and Elizabeth W. Karlson¹⁹, ¹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ²2- Rheumatology Research Unit,, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal, ³Rheumatology Department, Hospital Garcia de Orta, E.P.E., Almada, Portugal, ⁴Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ⁵Seebmo, Hospital de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, ⁶Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Research Unit, Instituto Medicina Molecular, Lisbon, Portugal, ⁸Rheumatology Department, Santa Maria Hospital, Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, ¹⁰Rheumatology Department, Unidade Local de Saude, Ponte de Lima, Portugal, ¹¹Reumatology, Instituto Portugues Reumatologia, Lisbon, Portugal, ¹²Rheumatology, Instituto Português de Reumatologia, Lisboa, Portugal, ¹³Rheumatology, Hospitais da Universidade de Coimbra, Coimbra, Portugal, ¹⁴Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ¹⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ¹⁷Serviço de Reumatologia, Centro Hospitalar e Universitário de Coimbra – Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, ¹⁸Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, ¹⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Some of the allelic variants associated with rheumatoid arthritis (RA) susceptibility are related to tumor necrosis factor (TNF) signaling pathways. We hypothesized that they…
Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Ozgur Tunceli¹, Jeffrey R. Curtis², Tatia C. Woodward³, Siting Zhou¹, Yen-Wen Chen⁴ and Ancilla W. Fernandes³, ¹HealthCore, Inc., Wilmington, DE, ²Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ³MedImmune, LLC, Gaithersburg, MD, ⁴HealthCore, Inc, Wilmington, DE
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…
Abstract Number: 2126 • 2012 ACR/ARHP Annual Meeting
Changes of Serological Markers in the Course of Traditional and Biological Disease Modifying Therapy of Rheumatoid Arthritis
Christoph Böhler¹, Helga Radner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) are established markers in the diagnostic approach to rheumatoid arthritis (RA). Both auto-antibodies (AAB) also…
Abstract Number: 1839 • 2012 ACR/ARHP Annual Meeting
The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort
Stéphanie Emilie¹, Cécile Gaujoux-Viala², Benjamin Granger³, Anne-Christine Rat⁴, Bernard Combe⁵ and Bruno Fautrel⁶, ¹Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, ²Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: The European League Against Rheumatism recommends tight control of rheumatoid arthritis (RA). However, tight control of RA may depend on several factors, including patient…
Abstract Number: 1842 • 2012 ACR/ARHP Annual Meeting
Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data From the Consortium of Rheumatology Researchers of North America
Sameer Kotak¹, Andrew S. Koenig², David H. Collier³, Katherine C. Saunders⁴, Ping He⁵, Joel M. Kremer⁶ and George W. Reed⁷, ¹Specialty Care, Pfizer Inc., New York, NY, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Corrona, LLC., Southborough, MA, ⁵UMASS Medical School, Worcester, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Studies on patients with severe rheumatoid arthritis (RA) are widely reported. However, limited data are available on patients with moderate disease activity (MOD). Recent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].